Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspacytarabine in Unfit Newly-Diagnosed AML
NCT03435848Phase 2Completed
- Sponsor
- BioSight
- Start
- Aug 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of aspacytarabine in acute myeloid leukemia (AML), sponsored by BioSight. Started Aug 2018; status: completed.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03435848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435848.